Turning Point Presents Results of Repotrectinib in P-I/II TRIDENT-1 Study for the Treatment of Solid Tumors at AACR-NCI-EORTC 2021

Shots:

The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26, 2021 cutoff data
The preliminary efficacy analysis in both population showed cORR (41% & 48%); 3 patients achieved SD with tumor regression of -21%, -23% & -27% in TKI-naïve; DoR (1.9+ to 7.4+ & 0.9+ to 15.1mos.), duration of treatment (0.9 to 30.7+ & 0.6 to 20.8mos.)
In 23 pretreated patients, 13 (57%) had NTRK solvent front mutations; cORR (62%), DoR (0.9+ to 13.7mos.), 3 patients had uPRs, 2 uPRs have been confirmed & 3rd patients were on treatment awaiting, was well tolerated, treatment discontinuation due to TEAEs (11%)

Click here to read full press release/ article | Ref: Globe Newswire | Image: Businesswire